$2.85
2.06%
Nasdaq, Nov 17, 04:00 pm EST.
ISIN
US8112921015
Symbol
SCYX

SCYNEXIS, Inc. Stock price

$2.85
-0.81 22.13% 1M
-2.63 48.01% 6M
-2.21 43.67% YTD
-1.77 38.29% 1Y
-10.11 78.01% 3Y
-50.59 94.67% 5Y
-284.35 99.01% 10Y
-717.15 99.60% 20Y
Nasdaq, Closing price Tue, Nov 17 2026
-0.06 2.06%
ISIN
US8112921015
Symbol
SCYX
Industry

Is SCYNEXIS, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,087 stocks worldwide.

Key metrics

Basic
Market capitalization
$28.4m
Enterprise Value
$-25.7m
Net debt
positive
Cash
$54.1m
Shares outstanding
10.0m
Valuation
P/E
negative
P/S | estimate
1.5 | 22.6
EV/Sales | estimate
negative | negative
EV/FCF | ex SBC
1.9 | 1.6
P/B
0.4
Financial Health
Equity Ratio
83.7%
Return on Equity
-17.4%
ROCE
-32.7%
ROIC
-
Debt/Equity
0.0
Share-Based Compensation & Dilution
SBC | % of Revenue
$2.4m | 12.3%
SBC as % of FCF
-
SBC Growth 1Y
-33.0%
Share Count Growth 1Y
103.1%
Shareholder Yield
-
Financials
Revenue | estimate
$19.2m | $1.3m
EBITDA
-
EBIT
$-22.6m
Net Income
$-10.2m
Free Cash Flow | ex SBC
$-13.3m | $-15.7m
Growth
Revenue | estimate
489.6% | -93.9%
EBITDA
-
EBIT
38.2%
Net Income
47.5%
Free Cash Flow
44.8%
Margin
Gross
-
EBITDA
-
EBIT
-117.6%
Net
-53.3%
Free Cash Flow | ex SBC
-69.3% | -81.6%
More
EPS
$-0.9
FCF per Share
$-1.3
Short interest
4.6%
Employees
18
Rev per Employee
$1.1m

SCYNEXIS, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a SCYNEXIS, Inc. forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a SCYNEXIS, Inc. forecast:

Buy
89%
Hold
11%

SCYNEXIS, Inc. Events

Past Events
MAR
31
Special Call - SCYNEXIS, Inc.
8 months ago

Financial data from SCYNEXIS, Inc.

Jun '26
+/-
%
19 19
490% 490%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 16 16
3% 3%
81%
- Research and Development Expense 26 26
6% 6%
137%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -23 -23
38% 38%
-118%
Net Profit -10 -10
48% 48%
-53%

In millions USD.

Don't miss a Thing! We will send you all news about SCYNEXIS, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

SCYNEXIS, Inc. Stock News

Neutral
GlobeNewsWire
●
13 days ago
JERSEY CITY, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today reported financial results for the third quarter ended September 30, 2026, and provided a corporate update highlighting the completion of a Phase 1 study of SCY-770 in ...
Neutral
GlobeNewsWire
●
20 days ago
JERSEY CITY, N.J., Oct. 29, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced that the SCYNEXIS senior leadership team will participate in the 3rd Annual Guggenheim Healthcare Innovation Conference, taking place November 9-11, 2026, in Boston.
Neutral
GlobeNewsWire
●
27 days ago
JERSEY CITY, N.J., Oct. 22, 2026 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”, or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced topline results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of the intravenous (IV) formulation of SCY-247, its seco...
More SCYNEXIS, Inc. News

Company Profile

SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several serious fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.

Head office United States
CEO Dr. Angulo
Employees 18
Founded 1999
Website www.scynexis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today